ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance 25/03/2026 Healthcare Innovative drugs Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD). Partners - Oryzon Genomics
MTBVAC moves toward its final stage: the vaccine candidate that could mark a turning point... 24/03/2026 Healthcare Innovative drugs According to WHO and ECDC data, 161,569 cases were reported in 2024 across 51 of the 53 countries in the European region... AseBio - Zendal
MTBVAC moves toward its final stage: the vaccine candidate that could mark a turning point... 24/03/2026 Zendal According to WHO and ECDC data, 161,569 cases were reported in 2024 across 51 of the 53 countries in the European region... AseBio - Zendal
ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax 23/03/2026 Healthcare Drug discovery Innovative drugs Recent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in... Partners - Oryzon Genomics
GSK opens Spain’s first maximum biosecurity laboratory 20/03/2026 Healthcare Innovative drugs Spain Prime Minister, Pedro Sánchez, recently visited the first maximum biosafety level (BSL-4) laboratory in Spain... Partners - GSK
AseBio promotes in Brussels the vision of the Spanish biotechnology sector on the Biotech ... 23/03/2026 Healthcare Rare diseases Innovative drugs Advanced therapies EU projects Our Director General, Ion Arocena, participated in the latest meeting of the MEP Interest Group “EU Biotech and Life... AseBio
ORYZON reports financial results and corporate update for quarter ended December 31st, 202... 02/03/2026 Healthcare Innovative drugs Personalized medicine Advanced therapies Financing Strong cash position at year-end 2025: $33.3 million (€28.4 million). Partners - Oryzon Genomics
ORYZON receives European Medicines Agency approval to initiate a Phase II study of iadadem... 24/02/2026 Healthcare Innovative drugs Essential thrombocythemia is the most common type of myeloproliferative neoplasm (MPN) and is associated with an... Partners - Oryzon Genomics
Childhood Cancer Needs Greater Awareness and Stable Funding to Accelerate Innovative Thera... 15/02/2026 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies Marina Salmón, Head of Project Evaluation at the Scientific Foundation of the Spanish Association Against Cancer, a... AseBio - Fundación Científica de la Asociación Española Contra el Cáncer
Childhood Cancer Needs Greater Awareness and Stable Funding to Accelerate Innovative Thera... 15/02/2026 Fundación Científica de la Asociación Española Contra el Cáncer In Spain, around 1,500 cases of childhood cancer are diagnosed each year (1% of the total), making research more... AseBio - Fundación Científica de la Asociación Española Contra el Cáncer
